Brean Murray Initiates Coverage on Auxilium Pharmaceuticals (AUXL) with a Sell
More News related to AUXL
- Unusual 11 Mid-Day Movers 12/18: ARYX, GIII, MU, XL Higher; CPY, ADLR, TTWO, SIMG Lower
- BenchmarkJournal.com (Complimentary) Analyst Review for and EXPE, GOLD, AUXL and ASTM
- Morning Movers 12/18: DVAX, ARYX, NOBH, AUXL Higher; CPY, TTWO, TNC, CVD Lower
- Auxilium (AUXL) and Pfizer (PFE) Enter Agreement to Commercialize XIAFLEX(TM) in Europe
- Auxilium (AUXL) In Development Agreement With Pfizer (PFE)
Brean Murray initiates coverage on Auxilium Pharmaceuticals (Nasdaq: AUXL) with a Sell rating and
$18 target price.
Brean analyst says, "We believe Auxilium at a $1.47 billion valuation is priced to perfection and prematurely reflects robust commercial success for XIAFLEX, while we expect XIAFLEX to receive a narrow labeling and a slower market penetration if approved based on the data released so far."
Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians.
Related Categories
New CoverageStocks Mentioned
-0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
